Tecon Biology Co., Ltd. Class A

As of June 30, 2026, Tecon Biology Co., Ltd. Class A carries a market capitalization of 8.61B, placing it among publicly traded companies globally. Its enterprise value stands at 14.43B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Tecon Biology Co., Ltd. Class A's next confirmed earnings release is scheduled for October 26, 2026.

As of June 30, 2026, Tecon Biology Co., Ltd. Class A has 1.37B shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Tecon Biology Co., Ltd. Class A maintains a current ratio of 1.31, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Tecon Biology Co., Ltd. Class A recorded 22.56M in income tax expense.

As of the close on October 23, 2026, Tecon Biology Co., Ltd. Class A's stock has gained approximately 7.31% over the past 52 weeks. The 50-day moving average sits at 7.66, while the 200-day moving average is 7.25.

As of June 30, 2026, Tecon Biology Co., Ltd. Class A holds 2.90B in cash and equivalents against 6.53B in total debt, resulting in a net debt position of 2.76B. Total book value stands at 6.34B, with working capital of 2.10B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Tecon Biology Co., Ltd. Class A paid dividends of 0.09 per share.

Tecon Biology Co., Ltd. Class A's most recent stock split took place on May 20, 2015 with a 1:2 split ratio.